ASH 2020 | RIC allogeneic HCT for high-risk MDS
Corey Cutler
• 15 Jan 2021
Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the BMT CTN 1102 trial (NCT02016781), comparing reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) to non-transplant therapies in patients aged 50-75 with advanced myelodysplastic syndromes (MDS). The study observed a significant overall survival (OS) advantage in older patients who had Int-2 and high-risk MDS and were RIC HCT candidates with HLA-matched donors, compared to those without a donor. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
